ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PLYX / forecast
TNXP (25) RTSN (51) TLSA (47) RLYB (38) ⌘ Pro Terminal →

Polaryx Therapeutics Inc. (PLYX) 12-Month Stock Forecast & Price Target Cone

$1.75 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.75

Polaryx Therapeutics Inc. (PLYX) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $87.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PLYX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PLYX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Polaryx Therapeutics Inc. (NASDAQ: PLYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.75 (0.00% 1D, market cap $87.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PLYX ranks #888 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PLYX compare to TNXP and RTSN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PLYX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TNXP (Tonix Pharmaceuticals Holding Corp.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $88.3M) and RTSN (Retension Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $89.1M). Among the 5-stock peer group, PLYX leads on earnings multiple (N/A) while PLYX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PLYX?
▼

Per PLYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002075320), Polaryx Therapeutics Inc. generated $21.9M in revenue (+79.7% YoY), -$9.0M in net income, and -$3.9M in free cash flow against $5.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.75 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (4)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.7% Base Target
$51 Bull$2 Base$1 Bear
📬 FREE PLYX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PLYX)Realized 20D OHLCV Swing Band: ±11.9%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY PLYX SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (37% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$1.97-1.5% Next Q
Q2 (-2Q)
32
Grade E$1.94-2.6% Next Q
Q3 (-1Q)
30
Grade E$1.89-7.4% Next Q
Current
27
Grade E$1.75-10.3% Hist 90D α
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PLYX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PLYX currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.99) and Max Pain ($1.84) forces dealer call-delta covering toward $51.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PLYX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PLYX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PLYX Position Size: $10,000

Shares at $1.75: 5714.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.18
$6,743
$-3,257 (-32.6%)
12M Consensus BaseTarget $1.51
$8,629
$-1,371 (-13.7%)
12M Bull Case BreakoutTarget $51.36
$293,486
+$283,486 (+2834.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$4869%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLYX)

  • ✓Walkthrough of PLYX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PLYX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.45%🛡️ HOLDING TREND SUPPORT
2026-11-04O $1.75H $1.75L $1.75C $1.75VOL 30.2K
RES: $2.24SUP: $1.72SMA50: $1.99SMA200: $3.62
$6.49$5.20$3.91$2.62$1.33RES $2.24SUP $1.72$1.752026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PLYX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PLYX Butterfly Map → + Track PLYX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +79.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PLYX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PLYX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PLYX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLYX)

Health Care Rank #888 of 1015 ⚔️ TNXP vs PLYX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PLYX vs. TNXP, RTSN, TLSA, RLYB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Polaryx Therapeutics Inc. (PLYX) ranks #888 by composite RQD confidence (27/100, grade E) and #673 by equity capitalization ($87.2M). Within this direct 5-issuer industry benchmark cohort, PLYX leads on earnings valuation at N/A trailing P/E, while PLYX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with PLYX at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PLYX ACTIVE
Polaryx Therapeutics Inc.
E 27/100 — — -35.0% 0.00% $87.2M Benchmark Subject
TNXP
Tonix Pharmaceuticals Holding Corp.
E 25/100 — 49.3% -35.0% +0.98% $88.3M /tnxp-vs-plyx →
RTSN
Retension Pharmaceuticals Inc.
D 51/100 — — — -0.53% $89.1M /rtsn-vs-plyx →
TLSA
Tiziana Life Sciences Ltd.
D 47/100 — — — -16.25% $85.3M /tlsa-vs-plyx →
RLYB
Rallybio Corporation
D- 38/100 — — -35.0% +1.42% $84.9M /rlyb-vs-plyx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002075320 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Polaryx Therapeutics Inc. (PLYX) reported GAAP revenue of $21.9M (+79.7% vs. FY2024 revenue of $12.2M ) , GAAP net income of -$9.0M, operating cash flow of -$3.9M, and free cash flow of -$3.9M (-53.3% YoY). On the balance sheet, PLYX closed FY2025 with $5.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $21.9M -$9.0M -$3.9M -$3.9M $5.2M —
FY2024 (FY) 2024-12-31 $12.2M -$30.4M -$2.6M -$2.6M $5.0M —

3. PLYX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PLYX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Polaryx Therapeutics Inc. (NASDAQ: PLYX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.75 (0.00% 1D, market cap $87.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PLYX ranks #888 in composite RQD confidence.

How does PLYX compare to TNXP and RTSN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PLYX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TNXP (Tonix Pharmaceuticals Holding Corp.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $88.3M) and RTSN (Retension Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $89.1M). Among the 5-stock peer group, PLYX leads on earnings multiple (N/A) while PLYX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PLYX?

Per PLYX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002075320), Polaryx Therapeutics Inc. generated $21.9M in revenue (+79.7% YoY), -$9.0M in net income, and -$3.9M in free cash flow against $5.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PLYX trading relative to its 50-day, 200-day, and 52-week technical levels?

PLYX last traded at $1.75 (0.00% on volume of 30,245 shares), positioning the stock -12.06% below its 50-day simple moving average ($1.99) and -51.66% below its 200-day simple moving average ($3.62). Across its 52-week range of $1.73 to $48.91, PLYX sits at the 0.0% percentile with a 14-day RSI of 34.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($1.54 to $1.96).

Direct Sub-Reports: PLYX RQD Cockpit PLYX 12M Forecast PLYX Earnings & Move PLYX Dividends & DRIP PLYX Insiders & 13F PLYX Whale Options PLYX Profit Sankey PLYX News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

PLYX — Polaryx Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Polaryx Therapeutics Inc. (PLYX) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.75 (0.00% 1D, market capitalization $87.2M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -4.25%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Polaryx Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Polaryx Therapeutics Inc. (PLYX) reported $21.9M in annual revenue (up from $12.2M in FY2024, +79.7% YoY) and -$9.0M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($12.2M revenue, -$30.4M net income) through FY2025, PLYX scaled operating cash flow to -$3.9M and free cash flow to -$3.9M, backed by $5.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -4.25% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.73 – $48.91 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations are — A prospective investor should note that the absence of mapped dependencies means second-order ripples cannot be traced from this dataset.

  • Key Question #1: Can PLYX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $21.9M and free cash flow of -$3.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PLYX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PLYX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Polaryx Therapeutics Inc. (PLYX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PLYX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PLYX Bull vs. Bear Conversation Board — What's Your Call at $1.75?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PLYX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PLYX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $2.29 (+30.9%)
📌 Pinned Debate

Cash rose from $4.6M to $5.1M across the two reported years, and the 52-week low of $1.71 sits below the current price of $1.86.

Don't sleep on PLYX's setup in Health Care. Cash rose from $4.6M to $5.1M across the two reported years, and the 52-week low of $1.71 sits below the current price of $1.86.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (27/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@DeepValue_CFA Agree on the RQD 27/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.75 and keeping dry powder in case we test $1.63.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.38 (-21.1%)
Spot @ $1.75

Negative ROIC of -35% and an FCF yield of -4.25% alongside zero reported revenue and a net loss of -$30.4M in FY 2024 point to a cash e

Sitting on the sidelines or leaning short PLYX above $1.75. Negative ROIC of -35% and an FCF yield of -4.25% alongside zero reported revenue and a net loss of -$30.4M in FY 2024 point to a cash engine that is not self-funding.. Until Fundamental Cash Engine (4/20) and FCF yield (-4.25%) inflect higher, upside is capped near $48.91.

LIVE TAPE